This question tests knowledge of fluoroquinolone dosing adjustments in severe renal impairment. The patient has a creatinine clearance of 22 mL/min, which requires significant dose adjustment for levofloxacin to prevent accumulation and toxicity. For severe pneumonia, levofloxacin 750 mg is typically given daily, but with CrCl 20-49 mL/min, the interval should be extended to every 48 hours while maintaining the 750 mg dose. Option A (no adjustment) would lead to drug accumulation and increased risk of QT prolongation and CNS effects. Option C reduces the dose too much and would be suboptimal for pneumonia treatment. Option D increases frequency inappropriately and would worsen toxicity risk. The clinical pearl is that fluoroquinolones require interval extension (not dose reduction) in renal impairment to maintain adequate peak concentrations while preventing accumulation.

This question addresses refeeding syndrome prevention in a malnourished patient starting TPN. The patient has multiple electrolyte deficiencies (low potassium, magnesium, and phosphate) and has been NPO for 7 days, placing him at high risk for refeeding syndrome. The correct approach is to replete electrolytes in the TPN and supplement thiamine before aggressive nutrition support to prevent cardiac and neurologic complications. Holding all electrolytes (option B) would worsen deficiencies and increase refeeding risk. Adding calcium chloride and phosphate together (option C) would cause precipitation and is incompatible. Starting maximum lipids while omitting dextrose (option D) doesn't address the electrolyte issues and could worsen the metabolic state. The clinical pearl is that malnourished patients require electrolyte repletion and thiamine supplementation before initiating aggressive nutrition support to prevent potentially fatal refeeding syndrome.

This question tests knowledge of urgent warfarin reversal in life-threatening bleeding. The patient has a supratherapeutic INR (6.2) with active GI bleeding and hemodynamic instability requiring immediate reversal. The combination of vitamin K 10 mg IV plus 4-factor PCC provides the fastest and most complete reversal, with PCC working within minutes and vitamin K sustaining the reversal. Vitamin K alone (option B) takes 12-24 hours for effect, which is too slow for urgent reversal. FFP alone (option C) requires large volumes, takes longer to administer, and is less effective than PCC. Protamine (option D) reverses heparin, not warfarin. The key principle is that life-threatening warfarin-associated bleeding requires both immediate reversal with PCC and sustained reversal with vitamin K for optimal outcomes.

This question tests the concept of preventing nephrotoxicity with acyclovir in renal impairment. The key patient-specific factor is the patient's chronic kidney disease with SCr 2.8 mg/dL, increasing risk for crystal nephropathy. Option B is the best choice because dose adjustment (e.g., 10 mg/kg q24h) and hydration reduce crystal formation and maintain efficacy. Option A is incorrect as rapid push increases nephrotoxicity; option C is suboptimal as fluids are needed to prevent crystals; option D is inappropriate as topical acyclovir is ineffective for encephalitis. Adjust acyclovir dose by CrCl and infuse over 1 hour with hydration. A decision framework is to monitor urine output and SCr daily during therapy.

This question tests the concept of benzodiazepine selection in alcohol withdrawal with hepatic impairment. The key patient-specific factor is the patient's elevated liver enzymes, affecting metabolism of certain benzodiazepines. Option B is the best choice because lorazepam undergoes glucuronidation, which is less impaired in liver disease, making it safer for intermittent or continuous use. Option A is incorrect as diazepam has prolonged half-life in cirrhosis; option C is suboptimal as midazolam is hepatically oxidized; option D is inappropriate as chlordiazepoxide is oral and hepatically metabolized. Prefer lorazepam or oxazepam in hepatic dysfunction for withdrawal. A clinical pearl is to use CIWA-Ar scores to guide symptom-triggered dosing.

This question tests the concept of recognizing and managing heparin-induced thrombocytopenia (HIT). The key patient-specific factor is the significant platelet drop (>50%) and new bruising after 5 days of heparin, suggestive of HIT. Option B is the best choice because stopping heparin and starting a non-heparin anticoagulant (e.g., argatroban) prevents thrombosis while evaluating with HIT assays. Option A is incorrect as continuing heparin risks severe complications; option C is suboptimal as warfarin alone increases thrombosis in acute HIT; option D is inappropriate as vitamin K does not reverse heparin. Calculate 4T score for HIT suspicion and confirm with assays. A clinical pearl is to avoid all heparins in suspected HIT and use direct thrombin inhibitors.

This question evaluates knowledge of IV drug compatibility and safe administration practices. Amiodarone and furosemide are incompatible when co-infused through the same line due to precipitation risk, which could cause catheter occlusion or embolism. The safest approach is to use a separate IV line or dedicated lumen for amiodarone to avoid any compatibility issues. Simply having clear solutions (option B) doesn't guarantee compatibility. Mixing drugs directly in the same bag (option C) is dangerous and could cause immediate precipitation. IV push amiodarone (option D) is only used in cardiac arrest situations and doesn't solve the compatibility issue. The clinical principle is that IV drug compatibility must be verified before Y-site administration, and when in doubt, separate lines should be used to ensure patient safety.

This question tests knowledge of chemotherapy premedication protocols to prevent hypersensitivity reactions. Paclitaxel is formulated with Cremophor EL, which frequently causes hypersensitivity reactions including anaphylaxis. Standard premedication includes a corticosteroid (dexamethasone), H1 blocker (diphenhydramine), and H2 blocker (famotidine or ranitidine) given before infusion to significantly reduce reaction risk. Leucovorin rescue (option B) is used with methotrexate, not paclitaxel. Avoiding premedication (option C) would be dangerous given the high reaction risk. IV push administration (option D) would increase reaction risk and is never appropriate for paclitaxel. The key principle is that taxane chemotherapy requires specific premedication protocols to prevent potentially life-threatening hypersensitivity reactions, especially in patients with a history of drug reactions.

This question evaluates emergency management of anaphylaxis with appropriate epinephrine administration. The patient presents with classic anaphylaxis symptoms (wheezing and hypotension after bee sting) requiring immediate epinephrine. The correct dose is 0.3-0.5 mg (0.3-0.5 mL of 1:1000 solution) given intramuscularly in the mid-outer thigh, which provides rapid absorption and effect. Diphenhydramine alone (option B) or methylprednisolone alone (option C) are inadequate as they don't reverse bronchospasm or hypotension acutely. IV push epinephrine at 1:1000 concentration (option D) would deliver 10 times the appropriate dose and could cause severe hypertension, arrhythmias, or stroke. The clinical pearl is that IM epinephrine (1:1000) in the thigh is first-line for anaphylaxis, while IV epinephrine requires 1:10,000 dilution and is reserved for cardiac arrest or refractory shock.

This question tests the concept of electrolyte monitoring during amphotericin B therapy. The key patient-specific factor is the patient's baseline hypokalemia and hypomagnesemia, which amphotericin exacerbates via renal wasting. Option A is the best choice because frequent potassium and magnesium checks with repletion prevent arrhythmias and other complications. Option B is incorrect as INR is unaffected; option C is suboptimal as troponin is for cardiac injury; option D is inappropriate as lipase is unrelated. Monitor electrolytes daily and replete aggressively with amphotericin. A decision framework is to use liposomal formulations to reduce nephrotoxicity but still monitor closely.